David E. Robinson, former chief operating officer of ErbamontInc., is joining Ligand Pharmaceuticals as president and chiefexecutive officer. Robinson replaces Ligand's founder, HowardC. Birndorf, who will remain on the board as chairmanemeritus. The privately held San Diego company focuses onintracellular receptor technology.

Dr. Gerald A. Faich has been named chief executive officer ofGHBA/PACT Inc., a St. David's, Pa., pharmaceutical industrycontract research organization that conducts late-phaseclinical trials. Faich, who joined the company in 1990,replaces Dr. John J. Schrogie, who retired.

William D. Phillips, Ph.D., has been elected to a new seat on theboard of Celgene Corp. Until September, Phillips was associatedirector for industrial technology in the Office of Science andTechnology Policy under President Bush. Celgene(NASDAQ:CELG) of Warren, N.J., is developing fine and specialtychemicals and proprietary hazardous waste biotreatmentsystems.

American Biogenetic Sciences Inc. (NASDAQ:MBAXA) of NotreDame, Ind., has elected Robert Dilenschneider to its board.Dilenschneider, a former president of Hill & Knowlton, headshis own public relations firm.

Ribi ImmunoChem Research Inc. (NASDAQ: RIBI) of Hamilton,Mont., has elected Mark S. Germain, managing director of D.Blech & Co. Inc., to its board. Ribi is developingimmunostimulants.

Evan M. Lebson, vice president of financial operations atGenzyme Corp., has been promoted to vice president andtreasurer. In addition, the company has appointed James L.Warren corporate controller. Warren was previously vicepresident of finance and administration at Itek GraphixComposition Systems of AB Dick. The Cambridge, Mass.,company (NASDAQ:GENZ) develops novel therapeutic proteinsand biomaterials.

Matrix Pharmaceutical Inc. of Menlo Park, Calif., has appointedRichard E. Jones, Ph.D., vice president of research anddevelopment. Jones was vice president of pharmaceuticaldevelopment at Pharmetrix Corp. Privately held Matrix isdeveloping site-specific therapeutics for cancer andhyperproliferative skin diseases.

(c) 1997 American Health Consultants. All rights reserved.